Table 1.

A comprehensive list of the anti-ErbB family receptor therapies approved by the FDA for the clinical use to treat cancers.

Drug Name	Erbb Family Receptor Targeted	Cancer Type Treated
Gefitinib/Iressa	Tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations	First-line treatment of metastatic Non-small Cell Lung Cancer (NSCLC)
Erlotinib/Tarceva	An epidermal growth factor receptor (EGFR) inhibitor	Non-small Cell Lung Cancer or Pancreatic Cancer that has spread to other parts of the body (metastatic)
Lapatinib/Tarceva	Dual tyrosine kinase inhibitor which interrupts the HER2/neu and epidermal growth factor receptor (EGFR) pathways	HER-2 positive Breast Cancer
Cetuximab/Erbitux	EGFR receptor signaling	Colorectal Cancer, Head and Neck Cancer
Panitumumab/Vectibix	EGFR receptor signaling	Colorectal Cancer
Vandetanib/Caprelsa	Targets multiple kinase receptors including EGFR, VEGF, RET-tyrosine kinase	Thyroid Cancer
Necitumumab/Portrazza	EGFR receptor signaling	Metastatic Squamous Non-small-cell Lung Carcinoma (NSCLC)
Osimertinib/Togrisso	EGFR T790M mutation-positive metastatic non-small cell lung cancer	Metastatic Non-small Cell Lung Cancer